ABN: 97 084 464 193

Suite 1 A, Level 2

802 Pacific Highway

Gordon NSW 2072

P: +61 2 9844 5422

F: +61 2 9844 5445

ASX Announcement 21 January 2013 Update and Status review of HI-164 therapy for COPD

Bioxyne Limited (ASX: BXN) today announced it had taken possession of the individual patient database from the clinical study H-005 into the efficacy of its HI-164 therapy for chronic obstructive pulmonary disease (COPD).
Analysis of the full data-set has commenced, which will allow the Company to properly compare the information from Study H-005 with that of earlier studies. Preliminary status review is as follows: